AT166578T - lymphocyte stimulation of cytotoxic respond t- - Google Patents

lymphocyte stimulation of cytotoxic respond t-

Info

Publication number
AT166578T
AT166578T AT92917479T AT92917479T AT166578T AT 166578 T AT166578 T AT 166578T AT 92917479 T AT92917479 T AT 92917479T AT 92917479 T AT92917479 T AT 92917479T AT 166578 T AT166578 T AT 166578T
Authority
AT
Austria
Prior art keywords
cytotoxic
respond
lymphocyte stimulation
lymphocyte
stimulation
Prior art date
Application number
AT92917479T
Other languages
German (de)
Inventor
Syamal Raychaudhuri
William H Rastetter
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US73506991A priority Critical
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of AT166578T publication Critical patent/AT166578T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24954233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT166578(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/381Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus
    • Y02A50/384Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus
    • Y02A50/395Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Tick-borne encephalitis [TBE]
    • Y02A50/396Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Tick-borne encephalitis [TBE] the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
AT92917479T 1991-07-25 1992-07-24 lymphocyte stimulation of cytotoxic respond t- AT166578T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US73506991A true 1991-07-25 1991-07-25

Publications (1)

Publication Number Publication Date
AT166578T true AT166578T (en) 1998-06-15

Family

ID=24954233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92917479T AT166578T (en) 1991-07-25 1992-07-24 lymphocyte stimulation of cytotoxic respond t-

Country Status (28)

Country Link
US (2) US5585103A (en)
EP (1) EP0596032B2 (en)
JP (1) JP3939746B2 (en)
KR (1) KR100198868B1 (en)
AT (1) AT166578T (en)
AU (1) AU666127B2 (en)
BG (1) BG62240B1 (en)
BR (1) BR9206310A (en)
CA (1) CA2113720A1 (en)
CZ (1) CZ288048B6 (en)
DE (2) DE69225710T3 (en)
DK (1) DK0596032T4 (en)
ES (1) ES2117052T5 (en)
FI (2) FI108114B (en)
GE (1) GEP20012556B (en)
HU (2) HU220295B (en)
IE (1) IE922436A1 (en)
IL (1) IL102639A (en)
MX (1) MX9204376A (en)
NO (1) NO317203B1 (en)
OA (1) OA9880A (en)
PH (1) PH30906A (en)
RO (1) RO116459B1 (en)
RU (1) RU2129439C1 (en)
SK (1) SK282920B6 (en)
TW (1) TW349867B (en)
WO (1) WO1993001831A1 (en)
ZA (1) ZA9205614B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
ES2195317T3 (en) * 1997-01-30 2003-12-01 Chiron Corp Use of microparticles with adsorbed antigen to stimulate immune responses.
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP0983086B1 (en) * 1997-02-05 2007-08-29 Jean-Claude Bystryn pH-SENSITIVE LIPOSOMES AND OTHER TYPES OF ENCAPSULATED VACCINES CONTAINING IMMUNOMODULATORS, AND METHODS FOR MAKING AND USING SAME
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag A method of inactivating lipid-enveloped viruses
DE69823347T2 (en) * 1997-05-16 2005-05-12 Alberta Research Council, Edmonton Microfluidic system and process for its operation
US6632619B1 (en) * 1997-05-16 2003-10-14 The Governors Of The University Of Alberta Microfluidic system and methods of use
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Oil in water emulsions with saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6858386B1 (en) * 1998-05-21 2005-02-22 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
BR9914957A (en) * 1998-10-30 2001-07-24 Genetics Inst Inhibition of cytotoxic T cells by antagonists of P-selectin ligand (PSGL)
AT351905T (en) * 1998-11-10 2007-02-15 Univ Emory Mitogene regulators
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
CA2394914A1 (en) * 1999-11-22 2001-05-31 Susana Salceda A novel method of diagnosing, monitoring, staging, imaging and treating cancer
US7238471B1 (en) * 1999-11-23 2007-07-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US20020048777A1 (en) * 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
JP2004510408A (en) * 2000-05-26 2004-04-08 ディアデクサス インコーポレーテッド Diagnosis of colon cancer, monitoring, staging, imaging and treatment methods of
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US6663861B2 (en) 2000-11-09 2003-12-16 Antibodyshop A/S Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
AU2003253632A1 (en) * 2002-06-10 2003-12-22 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
JP2006516883A (en) 2002-09-19 2006-07-13 アメリカ合衆国 P. Arashi polypeptide, Capsicum fly polypeptide, and method of use
AT429487T (en) 2002-10-29 2009-05-15 Us Gov Health & Human Serv Lutzomyia longipalpic polypeptides and method of use
ES2398235T3 (en) * 2003-04-04 2013-03-14 Pah Usa 15 Llc Oil emulsions in microfluidized water and vaccine compositions
DE602004013331T2 (en) * 2003-07-24 2009-07-16 Merial Ltd. Vaccine formulations with oil-in-water emulsion
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
CA2618306C (en) 2005-08-08 2014-10-21 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
EP2397853B1 (en) 2006-03-14 2014-01-15 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
CA2646319A1 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Incorporated Methods and compositions based on shiga toxin type 1 protein
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201809043T4 (en) 2006-09-26 2018-07-23 Infectious Disease Res Institute vaccine composition comprising a synthetic adjuvant.
TWI441648B (en) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Foxp3 peptide vaccine
EP2918598B1 (en) 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CA2702586C (en) * 2007-10-18 2017-08-01 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
EP2324049B1 (en) 2008-08-04 2016-05-25 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
TWI494125B (en) 2009-06-05 2015-08-01 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants
CA2776922A1 (en) 2009-10-07 2011-04-14 Uvic Industry Partnerships Inc. Vaccines comprising heat-sensitive transgenes
US9181306B2 (en) 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health&Science University Methods for producing an immune response to tuberculosis
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2691530T (en) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
JP6030650B2 (en) 2011-07-18 2016-11-24 アメリカ合衆国 Methods and compositions for inhibiting polyomavirus-related pathologies
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9566329B2 (en) 2012-04-06 2017-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, attenuated rubella vector to express vaccine antigens
JP2015522540A (en) 2012-05-16 2015-08-06 イミューン デザイン コーポレイション vaccine for HSV-2
EA201492262A1 (en) 2012-06-06 2015-08-31 Бионор Иммуно Ас Construction of peptide frame
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
AU2013331328B2 (en) 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
BR112015025709A2 (en) 2013-04-18 2017-07-18 Immune Design Corp gla monotherapy for cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP3052127A1 (en) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015089469A1 (en) 2013-12-13 2015-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope tarp peptide vaccine and uses thereof
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP2019515047A (en) 2016-05-10 2019-06-06 ナジット テクノロジーズ, インコーポレイテッド Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3083142A (en) * 1958-02-27 1963-03-26 Glaxo Group Ltd Improved swine erysipelas vaccine
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0373280B2 (en) * 1984-08-15 1991-11-21 Shingijutsu Kaihatsu Jigyodan
DE3751772D1 (en) * 1986-10-20 1996-05-15 Chiron Corp A vaccine for treatment of HSV
US4778784A (en) * 1987-01-07 1988-10-18 Baylor College Of Medicine Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies

Also Published As

Publication number Publication date
HU9400202D0 (en) 1994-05-30
CZ15094A3 (en) 1994-07-13
DK0596032T4 (en) 2004-07-26
JP3939746B2 (en) 2007-07-04
ES2117052T5 (en) 2004-12-01
RU2129439C1 (en) 1999-04-27
ES2117052T3 (en) 1998-08-01
KR100198868B1 (en) 1999-06-15
IL102639D0 (en) 1993-01-14
EP0596032B1 (en) 1998-05-27
CA2113720A1 (en) 1993-02-04
EP0596032A4 (en) 1994-08-17
DK0596032T3 (en) 1998-10-12
HUT69784A (en) 1995-09-28
AU666127B2 (en) 1996-02-01
FI109335B1 (en)
DE69225710T3 (en) 2004-10-14
TW349867B (en) 1999-01-11
NO317203B1 (en) 2004-09-20
PH30906A (en) 1997-12-23
BR9206310A (en) 1995-04-25
HU211299A9 (en) 1995-11-28
FI940335A (en) 1994-03-24
SK282920B6 (en) 2003-01-09
DE69225710T2 (en) 1998-09-24
FI940335D0 (en)
AU2433892A (en) 1993-02-23
IL102639A (en) 1997-03-18
FI108114B (en) 2001-11-30
OA9880A (en) 1994-09-15
RO116459B1 (en) 2001-02-28
FI20011187A (en) 2001-06-05
SK8994A3 (en) 1994-11-09
CZ288048B6 (en) 2001-04-11
NO940218L (en) 1994-03-25
BG62240B1 (en) 1999-06-30
EP0596032B2 (en) 2004-04-07
EP0596032A1 (en) 1994-05-11
JPH06509344A (en) 1994-10-20
MX9204376A (en) 1993-02-01
US5585103A (en) 1996-12-17
IE922436A1 (en) 1993-01-27
NO940218D0 (en) 1994-01-21
US6270769B1 (en) 2001-08-07
HU220295B (en) 2001-11-28
WO1993001831A1 (en) 1993-02-04
ZA9205614B (en) 1993-04-20
GEP20012556B (en) 2001-07-10
DK596032T4 (en)
FI108114B1 (en)
DK596032T3 (en)
BG98410A (en) 1995-02-28
FI109335B (en) 2002-07-15
FI940335A0 (en) 1994-01-24
DE69225710D1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
DE69218658T3 (en) An implantable defibrillator system
DE69230645D1 (en) implant
DE68928017T2 (en) Reference electrode
DE69030767T2 (en) defibrillation
NO942923L (en) drugs
NO170326B (en) Dihydroksydifenylcykloalkaner
NO178264B (en) 11-
NO179539C (en) Antiprellinnretning
MX170604B (en) Dosage unit
DE69233035D1 (en) Targeted point-mutagenesis of dna
AT156026T (en) Iontophoretic administration device
DE69330373D1 (en) syringe
DE69325450D1 (en) Potentiation of antimicrobial effects
IT1229451B (en) Harvester
AT135463T (en) PH electrode
DE69216431D1 (en) Implantable line system
DE69232350T2 (en) Treatment of material
DE68928754D1 (en) Collagen-polymer-conjugates
DE68928345D1 (en) Confokales scan-endoscope
NO179500C (en) Skjöthylster
DE68928260T2 (en) Spektralkombinationsvorrichtung
DE69225470T2 (en) Treatment of waste
BR1100029A (en) Agents antiangìnicos of pirazolpirimidinonas
NO934105L (en) Over Balance-perforating and stimulation leringsmetode
DE69115471D1 (en) Device for iontophoretic administration of drugs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0596032

Country of ref document: EP

REN Ceased due to non-payment of the annual fee